Concepts (334)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Skin Neoplasms | 18 | 2025 | 625 | 6.020 |
Why?
|
| Dermatology | 9 | 2025 | 46 | 5.260 |
Why?
|
| Skin | 16 | 2025 | 605 | 3.450 |
Why?
|
| Skin Diseases | 8 | 2025 | 176 | 3.390 |
Why?
|
| Photochemotherapy | 10 | 2024 | 101 | 3.170 |
Why?
|
| Acne Vulgaris | 5 | 2024 | 36 | 2.760 |
Why?
|
| Education, Medical | 4 | 2024 | 252 | 2.320 |
Why?
|
| Keratosis, Actinic | 4 | 2024 | 13 | 1.930 |
Why?
|
| Melanoma | 6 | 2024 | 497 | 1.870 |
Why?
|
| Photosensitizing Agents | 9 | 2024 | 52 | 1.710 |
Why?
|
| Skin Diseases, Genetic | 2 | 2023 | 7 | 1.530 |
Why?
|
| Artificial Intelligence | 3 | 2025 | 398 | 1.480 |
Why?
|
| Nevus, Pigmented | 4 | 2023 | 58 | 1.460 |
Why?
|
| Skin Aging | 4 | 2025 | 32 | 1.410 |
Why?
|
| Mohs Surgery | 4 | 2024 | 28 | 1.380 |
Why?
|
| Dermatitis, Atopic | 3 | 2022 | 66 | 1.380 |
Why?
|
| Internship and Residency | 4 | 2021 | 1134 | 1.380 |
Why?
|
| Pigmentation Disorders | 2 | 2019 | 13 | 1.240 |
Why?
|
| Nevus | 3 | 2023 | 18 | 1.210 |
Why?
|
| Scalp Dermatoses | 2 | 2019 | 10 | 1.170 |
Why?
|
| Humans | 74 | 2025 | 96105 | 1.100 |
Why?
|
| Erythema | 4 | 2023 | 33 | 1.020 |
Why?
|
| Laser Therapy | 6 | 2024 | 151 | 0.990 |
Why?
|
| Phototherapy | 2 | 2016 | 36 | 0.980 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2024 | 1105 | 0.940 |
Why?
|
| Patient Education as Topic | 3 | 2024 | 378 | 0.940 |
Why?
|
| Sunscreening Agents | 1 | 2024 | 10 | 0.860 |
Why?
|
| Exosomes | 1 | 2025 | 60 | 0.860 |
Why?
|
| Melanosis | 1 | 2024 | 6 | 0.850 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 13 | 0.810 |
Why?
|
| Interleukin-4 | 2 | 2021 | 136 | 0.790 |
Why?
|
| Rejuvenation | 3 | 2024 | 21 | 0.780 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 2023 | 235 | 0.780 |
Why?
|
| Aminolevulinic Acid | 3 | 2019 | 23 | 0.770 |
Why?
|
| Vitamin A | 1 | 2022 | 28 | 0.770 |
Why?
|
| Rhinitis, Allergic | 1 | 2022 | 52 | 0.740 |
Why?
|
| Mouth Mucosa | 2 | 2019 | 71 | 0.730 |
Why?
|
| Urticaria | 1 | 2022 | 15 | 0.730 |
Why?
|
| Sebaceous Gland Neoplasms | 2 | 2019 | 8 | 0.710 |
Why?
|
| Exanthema | 1 | 2022 | 41 | 0.700 |
Why?
|
| Research Subjects | 1 | 2021 | 73 | 0.680 |
Why?
|
| Teaching Materials | 1 | 2020 | 14 | 0.660 |
Why?
|
| Dermatologists | 1 | 2020 | 2 | 0.650 |
Why?
|
| Drug Eruptions | 2 | 2021 | 35 | 0.650 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 9 | 0.650 |
Why?
|
| Ear Neoplasms | 1 | 2020 | 14 | 0.650 |
Why?
|
| Mucositis | 1 | 2020 | 18 | 0.650 |
Why?
|
| Margins of Excision | 1 | 2020 | 45 | 0.650 |
Why?
|
| Certification | 1 | 2020 | 66 | 0.650 |
Why?
|
| Private Practice | 1 | 2020 | 12 | 0.640 |
Why?
|
| Coronavirus | 1 | 2020 | 20 | 0.640 |
Why?
|
| Career Mobility | 1 | 2020 | 44 | 0.630 |
Why?
|
| Hyperpigmentation | 2 | 2017 | 7 | 0.630 |
Why?
|
| Low-Level Light Therapy | 1 | 2019 | 15 | 0.620 |
Why?
|
| SEER Program | 4 | 2021 | 235 | 0.620 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2019 | 4 | 0.620 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2019 | 24 | 0.610 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2024 | 569 | 0.610 |
Why?
|
| Silicone Gels | 1 | 2019 | 3 | 0.610 |
Why?
|
| Bacteremia | 1 | 2020 | 108 | 0.600 |
Why?
|
| Sarcoma, Kaposi | 1 | 2019 | 18 | 0.600 |
Why?
|
| Herpes Simplex | 1 | 2020 | 203 | 0.580 |
Why?
|
| Eyelids | 2 | 2016 | 24 | 0.580 |
Why?
|
| MicroRNAs | 2 | 2021 | 591 | 0.580 |
Why?
|
| Antineoplastic Agents | 3 | 2024 | 2418 | 0.570 |
Why?
|
| Pemphigoid, Benign Mucous Membrane | 1 | 2018 | 6 | 0.570 |
Why?
|
| Tomography, Optical Coherence | 5 | 2025 | 131 | 0.560 |
Why?
|
| United States | 8 | 2025 | 7768 | 0.550 |
Why?
|
| Pandemics | 2 | 2023 | 880 | 0.550 |
Why?
|
| Skin Diseases, Infectious | 1 | 2017 | 12 | 0.550 |
Why?
|
| Pain | 2 | 2019 | 426 | 0.540 |
Why?
|
| Licensure, Medical | 3 | 2021 | 22 | 0.510 |
Why?
|
| Mouth Neoplasms | 1 | 2019 | 202 | 0.510 |
Why?
|
| Diagnosis, Differential | 5 | 2023 | 1619 | 0.500 |
Why?
|
| Dermatologic Agents | 2 | 2017 | 77 | 0.490 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 1179 | 0.480 |
Why?
|
| Immunosuppressive Agents | 2 | 2017 | 995 | 0.460 |
Why?
|
| Pityriasis Rubra Pilaris | 2 | 2019 | 3 | 0.460 |
Why?
|
| Aspergillosis | 1 | 2015 | 39 | 0.460 |
Why?
|
| Blepharoplasty | 1 | 2015 | 8 | 0.450 |
Why?
|
| Opportunistic Infections | 1 | 2015 | 60 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 346 | 0.450 |
Why?
|
| Infant | 4 | 2023 | 3363 | 0.450 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 334 | 0.450 |
Why?
|
| Biological Products | 1 | 2017 | 179 | 0.450 |
Why?
|
| Patient Compliance | 1 | 2016 | 239 | 0.440 |
Why?
|
| Asthma | 1 | 2022 | 1051 | 0.430 |
Why?
|
| Photoacoustic Techniques | 2 | 2024 | 7 | 0.420 |
Why?
|
| Condylomata Acuminata | 1 | 2014 | 15 | 0.420 |
Why?
|
| Aged | 13 | 2025 | 20968 | 0.420 |
Why?
|
| Male | 23 | 2025 | 45863 | 0.410 |
Why?
|
| Sweet Syndrome | 2 | 2014 | 6 | 0.410 |
Why?
|
| Alphapapillomavirus | 1 | 2014 | 45 | 0.410 |
Why?
|
| Female | 25 | 2025 | 50028 | 0.410 |
Why?
|
| Skin Pigmentation | 3 | 2024 | 36 | 0.400 |
Why?
|
| Epidermis | 3 | 2024 | 104 | 0.390 |
Why?
|
| Middle Aged | 15 | 2025 | 28368 | 0.390 |
Why?
|
| Infant, Newborn | 3 | 2023 | 2614 | 0.350 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7229 | 0.330 |
Why?
|
| Antiviral Agents | 1 | 2014 | 504 | 0.320 |
Why?
|
| Esthetics | 3 | 2021 | 50 | 0.320 |
Why?
|
| Cicatrix | 2 | 2024 | 72 | 0.320 |
Why?
|
| Treatment Outcome | 7 | 2024 | 9175 | 0.320 |
Why?
|
| Hand Dermatoses | 1 | 2009 | 9 | 0.310 |
Why?
|
| Retrospective Studies | 5 | 2022 | 10287 | 0.300 |
Why?
|
| Dermis | 1 | 2009 | 30 | 0.300 |
Why?
|
| Sarcoidosis | 2 | 2020 | 75 | 0.300 |
Why?
|
| Ultraviolet Therapy | 1 | 2009 | 17 | 0.300 |
Why?
|
| Heart Transplantation | 1 | 2015 | 812 | 0.300 |
Why?
|
| Rare Diseases | 2 | 2019 | 71 | 0.290 |
Why?
|
| Biopsy, Needle | 2 | 2019 | 231 | 0.290 |
Why?
|
| Carcinoma, Basal Cell | 2 | 2024 | 63 | 0.270 |
Why?
|
| Color | 2 | 2019 | 87 | 0.270 |
Why?
|
| Age Factors | 3 | 2025 | 1963 | 0.260 |
Why?
|
| Administration, Topical | 2 | 2018 | 86 | 0.250 |
Why?
|
| Curriculum | 2 | 2021 | 615 | 0.250 |
Why?
|
| Severity of Illness Index | 3 | 2023 | 1979 | 0.240 |
Why?
|
| Rosacea | 1 | 2025 | 1 | 0.240 |
Why?
|
| Survival Rate | 2 | 2020 | 1985 | 0.230 |
Why?
|
| Cosmetic Techniques | 2 | 2016 | 28 | 0.230 |
Why?
|
| Edema | 2 | 2023 | 73 | 0.230 |
Why?
|
| Adult | 12 | 2025 | 28721 | 0.230 |
Why?
|
| Migraine Disorders | 1 | 2025 | 43 | 0.220 |
Why?
|
| Biomarkers | 3 | 2021 | 1930 | 0.220 |
Why?
|
| United States Food and Drug Administration | 1 | 2025 | 147 | 0.210 |
Why?
|
| Striae Distensae | 1 | 2024 | 1 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 847 | 0.210 |
Why?
|
| Administration, Cutaneous | 1 | 2024 | 61 | 0.210 |
Why?
|
| Dermatomycoses | 1 | 2023 | 11 | 0.200 |
Why?
|
| Patient Care | 1 | 2024 | 101 | 0.200 |
Why?
|
| Health Literacy | 1 | 2024 | 77 | 0.200 |
Why?
|
| Video Recording | 1 | 2024 | 214 | 0.190 |
Why?
|
| Retinoids | 1 | 2022 | 18 | 0.190 |
Why?
|
| Varicose Ulcer | 1 | 2022 | 6 | 0.190 |
Why?
|
| Child | 5 | 2022 | 7625 | 0.190 |
Why?
|
| Purpura | 2 | 2000 | 13 | 0.190 |
Why?
|
| Biopsy | 3 | 2023 | 1220 | 0.190 |
Why?
|
| Phenols | 1 | 2022 | 42 | 0.190 |
Why?
|
| Combined Modality Therapy | 2 | 2019 | 1773 | 0.190 |
Why?
|
| Hidradenitis | 1 | 2021 | 2 | 0.180 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2021 | 14 | 0.180 |
Why?
|
| Communicable Diseases | 1 | 2022 | 69 | 0.180 |
Why?
|
| Incidence | 2 | 2023 | 1715 | 0.180 |
Why?
|
| Ultrasonography | 1 | 2024 | 744 | 0.170 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2024 | 465 | 0.170 |
Why?
|
| Insulin Resistance | 2 | 2021 | 380 | 0.170 |
Why?
|
| Bronchogenic Cyst | 1 | 2021 | 5 | 0.170 |
Why?
|
| Dermoid Cyst | 1 | 2021 | 15 | 0.170 |
Why?
|
| Dermoscopy | 1 | 2020 | 7 | 0.170 |
Why?
|
| Up-Regulation | 2 | 2021 | 740 | 0.170 |
Why?
|
| Sex Factors | 2 | 2025 | 1133 | 0.170 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 7 | 0.160 |
Why?
|
| Ear, External | 1 | 2020 | 25 | 0.160 |
Why?
|
| Staphylococcus epidermidis | 1 | 2020 | 16 | 0.160 |
Why?
|
| Necrobiosis Lipoidica | 1 | 2020 | 2 | 0.160 |
Why?
|
| Accreditation | 1 | 2020 | 74 | 0.160 |
Why?
|
| Personnel Selection | 1 | 2020 | 64 | 0.160 |
Why?
|
| Necrosis | 3 | 2015 | 210 | 0.160 |
Why?
|
| Mannose-Binding Lectins | 1 | 2019 | 7 | 0.160 |
Why?
|
| Tattooing | 1 | 2019 | 5 | 0.160 |
Why?
|
| Mutagens | 1 | 2019 | 30 | 0.160 |
Why?
|
| Mice, Transgenic | 2 | 2021 | 1645 | 0.160 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 276 | 0.160 |
Why?
|
| Panuveitis | 1 | 2019 | 4 | 0.160 |
Why?
|
| Mastocytoma, Skin | 1 | 2019 | 1 | 0.150 |
Why?
|
| Corneal Ulcer | 1 | 2019 | 5 | 0.150 |
Why?
|
| Mastocytoma | 1 | 2019 | 4 | 0.150 |
Why?
|
| Scleritis | 1 | 2019 | 4 | 0.150 |
Why?
|
| Lupus Vulgaris | 1 | 2019 | 4 | 0.150 |
Why?
|
| Protective Factors | 1 | 2019 | 28 | 0.150 |
Why?
|
| Histiocytosis, Non-Langerhans-Cell | 1 | 2019 | 5 | 0.150 |
Why?
|
| S100 Proteins | 1 | 2019 | 53 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2019 | 7 | 0.150 |
Why?
|
| Antigens, CD1 | 1 | 2019 | 37 | 0.150 |
Why?
|
| Paraproteinemias | 1 | 2019 | 19 | 0.150 |
Why?
|
| Cultural Diversity | 1 | 2020 | 68 | 0.150 |
Why?
|
| Lectins, C-Type | 1 | 2019 | 89 | 0.150 |
Why?
|
| Interviews as Topic | 1 | 2020 | 376 | 0.150 |
Why?
|
| Simplexvirus | 1 | 2020 | 150 | 0.150 |
Why?
|
| Arthralgia | 1 | 2019 | 41 | 0.150 |
Why?
|
| Antigen-Antibody Complex | 1 | 2019 | 89 | 0.150 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 883 | 0.150 |
Why?
|
| Medicare | 1 | 2022 | 458 | 0.150 |
Why?
|
| Microscopy, Electron | 1 | 2019 | 510 | 0.150 |
Why?
|
| Vascular Diseases | 1 | 2000 | 123 | 0.150 |
Why?
|
| Minority Groups | 1 | 2020 | 154 | 0.150 |
Why?
|
| Anesthetics, Local | 1 | 2019 | 84 | 0.150 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2018 | 30 | 0.140 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 244 | 0.140 |
Why?
|
| Tumor Burden | 1 | 2019 | 322 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2021 | 553 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 9 | 0.140 |
Why?
|
| Keratinocytes | 1 | 2018 | 146 | 0.140 |
Why?
|
| Antigens, CD | 1 | 2019 | 481 | 0.140 |
Why?
|
| Wound Healing | 2 | 2019 | 378 | 0.130 |
Why?
|
| Lymphatic Metastasis | 1 | 2019 | 514 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 179 | 0.130 |
Why?
|
| Dermatitis, Phototoxic | 1 | 1997 | 2 | 0.130 |
Why?
|
| Motivation | 1 | 2020 | 310 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2021 | 611 | 0.130 |
Why?
|
| Telemedicine | 1 | 2020 | 229 | 0.130 |
Why?
|
| Neutrophils | 3 | 2021 | 332 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.130 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 901 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 353 | 0.130 |
Why?
|
| Immunity, Cellular | 1 | 2017 | 191 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1876 | 0.130 |
Why?
|
| Nocardia Infections | 1 | 2016 | 4 | 0.130 |
Why?
|
| Hospitalization | 1 | 2022 | 943 | 0.130 |
Why?
|
| Onychomycosis | 1 | 2016 | 1 | 0.120 |
Why?
|
| Intense Pulsed Light Therapy | 1 | 2016 | 1 | 0.120 |
Why?
|
| Telangiectasis | 1 | 2016 | 8 | 0.120 |
Why?
|
| Doxycycline | 1 | 2016 | 37 | 0.120 |
Why?
|
| Logistic Models | 2 | 2019 | 1268 | 0.120 |
Why?
|
| Hirsutism | 1 | 2016 | 61 | 0.120 |
Why?
|
| Surveys and Questionnaires | 1 | 2024 | 2860 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2020 | 436 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2020 | 441 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2017 | 555 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2021 | 854 | 0.120 |
Why?
|
| Cosmetics | 1 | 2015 | 7 | 0.110 |
Why?
|
| Young Adult | 2 | 2025 | 7025 | 0.110 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2021 | 841 | 0.110 |
Why?
|
| Life Change Events | 1 | 2015 | 50 | 0.110 |
Why?
|
| Cellulitis | 1 | 2014 | 19 | 0.110 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1828 | 0.110 |
Why?
|
| Injections, Intralesional | 1 | 2014 | 22 | 0.110 |
Why?
|
| Caustics | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cryotherapy | 1 | 2014 | 30 | 0.100 |
Why?
|
| Metabolic Syndrome | 1 | 2015 | 123 | 0.100 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2534 | 0.100 |
Why?
|
| Prognosis | 1 | 2021 | 4028 | 0.100 |
Why?
|
| Animals | 7 | 2024 | 28891 | 0.100 |
Why?
|
| Child Development | 1 | 2015 | 174 | 0.100 |
Why?
|
| Muir-Torre Syndrome | 1 | 2012 | 5 | 0.100 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2015 | 125 | 0.100 |
Why?
|
| Facial Neoplasms | 1 | 2012 | 26 | 0.100 |
Why?
|
| Adolescent | 4 | 2025 | 9895 | 0.100 |
Why?
|
| Risk Factors | 4 | 2019 | 5961 | 0.100 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 647 | 0.090 |
Why?
|
| Viral Proteins | 1 | 2014 | 289 | 0.090 |
Why?
|
| Inflammation | 1 | 2018 | 1063 | 0.090 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2015 | 287 | 0.090 |
Why?
|
| Patient Selection | 1 | 2016 | 709 | 0.090 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1670 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2480 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 2642 | 0.080 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 635 | 0.080 |
Why?
|
| Adenoma | 1 | 2012 | 260 | 0.080 |
Why?
|
| HIV Infections | 1 | 2019 | 974 | 0.080 |
Why?
|
| Signal Transduction | 1 | 2021 | 3581 | 0.080 |
Why?
|
| Mice | 2 | 2021 | 12537 | 0.080 |
Why?
|
| Genotype | 1 | 2014 | 1881 | 0.080 |
Why?
|
| Rabbits | 3 | 2000 | 639 | 0.070 |
Why?
|
| Puerperal Disorders | 1 | 2009 | 37 | 0.070 |
Why?
|
| Down-Regulation | 2 | 2021 | 526 | 0.070 |
Why?
|
| Obesity | 2 | 2015 | 1030 | 0.070 |
Why?
|
| Dermatofibrosarcoma | 1 | 2008 | 14 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 777 | 0.070 |
Why?
|
| Porphyrins | 2 | 1998 | 37 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 771 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2012 | 882 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 56 | 0.060 |
Why?
|
| Apoptosis | 2 | 2021 | 1756 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2024 | 196 | 0.050 |
Why?
|
| Support Vector Machine | 1 | 2023 | 25 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1957 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 38 | 0.050 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2000 | 192 | 0.050 |
Why?
|
| Burns | 1 | 2024 | 150 | 0.050 |
Why?
|
| Hair Removal | 1 | 2002 | 14 | 0.050 |
Why?
|
| Sweat Glands | 1 | 2021 | 6 | 0.040 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2021 | 41 | 0.040 |
Why?
|
| Cold Temperature | 1 | 2002 | 162 | 0.040 |
Why?
|
| Daunorubicin | 1 | 2021 | 78 | 0.040 |
Why?
|
| Mercaptopurine | 1 | 2021 | 53 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2024 | 1267 | 0.040 |
Why?
|
| Prevalence | 1 | 2025 | 1349 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 938 | 0.040 |
Why?
|
| Leg Ulcer | 1 | 2001 | 7 | 0.040 |
Why?
|
| Cytarabine | 1 | 2021 | 225 | 0.040 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2001 | 20 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2021 | 313 | 0.040 |
Why?
|
| Ischemia | 1 | 2022 | 256 | 0.040 |
Why?
|
| Pruritus | 1 | 2000 | 30 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 242 | 0.040 |
Why?
|
| Blood Vessels | 1 | 2000 | 92 | 0.040 |
Why?
|
| Software | 1 | 2024 | 698 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2001 | 193 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2024 | 484 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 1319 | 0.040 |
Why?
|
| Lymphangiogenesis | 1 | 2018 | 41 | 0.040 |
Why?
|
| Rats | 1 | 2024 | 4155 | 0.030 |
Why?
|
| Maximum Allowable Concentration | 1 | 1997 | 2 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1471 | 0.030 |
Why?
|
| Protoporphyrins | 1 | 1997 | 19 | 0.030 |
Why?
|
| Radiation Injuries, Experimental | 1 | 1997 | 41 | 0.030 |
Why?
|
| Fluorescence | 1 | 1997 | 106 | 0.030 |
Why?
|
| Nocardia | 1 | 2016 | 2 | 0.030 |
Why?
|
| Light | 1 | 1997 | 297 | 0.030 |
Why?
|
| Recurrence | 2 | 2014 | 1218 | 0.030 |
Why?
|
| Algorithms | 1 | 2024 | 2015 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 813 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 4671 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 39 | 0.030 |
Why?
|
| Time Factors | 3 | 2002 | 5580 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2014 | 28 | 0.030 |
Why?
|
| Quality of Life | 1 | 2023 | 1816 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2015 | 175 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2777 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2015 | 815 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1176 | 0.020 |
Why?
|
| Comorbidity | 1 | 2015 | 1011 | 0.020 |
Why?
|
| Cholelithiasis | 1 | 1989 | 36 | 0.020 |
Why?
|
| Dietary Fats | 1 | 1989 | 137 | 0.020 |
Why?
|
| Furocoumarins | 1 | 2007 | 2 | 0.020 |
Why?
|
| New Hampshire | 1 | 2007 | 3 | 0.020 |
Why?
|
| Fluoroquinolones | 1 | 2007 | 20 | 0.020 |
Why?
|
| Diet | 1 | 1989 | 460 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2007 | 198 | 0.020 |
Why?
|
| Trauma Severity Indices | 1 | 2002 | 47 | 0.010 |
Why?
|
| Skin, Artificial | 1 | 2001 | 8 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2008 | 3974 | 0.010 |
Why?
|
| Liposomes | 1 | 1998 | 99 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2001 | 1023 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1998 | 297 | 0.010 |
Why?
|
| Drug Carriers | 1 | 1998 | 88 | 0.010 |
Why?
|
| Iontophoresis | 1 | 1997 | 4 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 1997 | 262 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1809 | 0.010 |
Why?
|
| Plant Oils | 1 | 1989 | 8 | 0.000 |
Why?
|
| Occupations | 1 | 1989 | 25 | 0.000 |
Why?
|
| Chi-Square Distribution | 1 | 1989 | 363 | 0.000 |
Why?
|
| Smoking | 1 | 1989 | 653 | 0.000 |
Why?
|